NCT03742245View on ClinicalTrials.gov

Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

September 1, 2025

Study Completion Date

March 1, 2026

Conditions
Breast Cancer MetastaticBreast Cancer
Interventions
DRUG

Olaparib

PARP inhibitor

DRUG

Vorinostat

HDAC inhibitor

Trial Locations (1)

77030

RECRUITING

Houston Methodist Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER